Novel combination therapy found to significantly reduce spleen volume in patients with myelofibrosis
Combining the JAK inhibitor ruxolitinib with the BCL-xL inhibitor navitoclax was twice as effective in reducing enlarged spleens—a major indicator of clinical improvement—compared with standard-of-care ruxolitinib monotherapy ...
Dec 11, 2023
0
0